CYTEGRITY
Live / Applied — Second extension granted (statement of use) (as of 11 Feb 2026)
What this means for you
Not registered yet, but its 20 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98232757
- Mark type
- Stylized text
- Filed
- 20 Oct 2023
- Published for opposition
- 14 Jan 2025
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 001 — Chemicals: Cell lines, being cells, for scientific and research use; Cells for scientific, laboratory or medical research; Biological preparations, namely, viral vectors and gene vectors for scientific, laboratory or medical research; Cell lines for clinical laboratory use; cell lines for scientific research, namely, cell lines for gene expression and for the synthesis of biological compounds; cells for scientific, laboratory, or medical research, namely, cells for gene expression systems and for the synthesis of biological compounds; viral vectors for use in science and industry
- Class 005 — Pharmaceuticals: Cell lines for medical purposes; Cells for medical or clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating cancer, tumors, genetic diseases, immunodeficiency conditions, stem cell transplantation, and transplant medicine; Biological preparations, namely, viral vectors and gene therapy vectors for therapeutic use and clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for treating a wide range of diseases, illnesses or conditions; Cell lines for medical purposes, namely, cell therapy; Cell lines for medical purposes, namely, immunotherapy; Cell lines for medical purposes, namely, for use as therapeutics to repair, replace or preserve cells and tissues; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating genetically engineered tissues and for treating transplant conditions; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating viral and infectious diseases; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders; viral vectors for medical use relating to gene therapy; gene therapy vectors for medical use
Owner
- CSL Behring Gene Therapy, Inc., Pasadena, CA, US
- CSL Behring Gene Therapy, Inc., Pasadena, CA, US
Prosecution history
- 11 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Feb 2026 — SOU EXTENSION 2 GRANTED
- 11 Feb 2026 — SOU EXTENSION 2 FILED
- 11 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 25 Aug 2025 — ASSIGNED TO EXAMINER
- 11 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Aug 2025 — SOU EXTENSION 1 GRANTED
- 11 Aug 2025 — SOU EXTENSION 1 FILED
- 11 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 14 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jan 2025 — PUBLISHED FOR OPPOSITION
- 08 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED